Imagen de Portada

RAPID HEALING OF LIVER HEALTH ALONG WITH PREVENTING IT FROM CONVERTING INTO ACUTE TO CHRONIC LIVER DISEASE BYAYURVEDIC MANAGEMENT INTHE VIEWPOINT OFYAKRIT VIKARA: A CASE STUDY

Fuente: Zenodo

Guardado en:

Detalles Bibliográficos
Autores principales:	Acharya Manish, Gitika Chaudhary, Richa, Yogesh Handa, Tanu Rani
Formato:	Recurso digital
Publicado:	Zenodo 2025
Materias:	Liver disorders Yakrit vikar Rakta dhatu Vomiting LFT Liver cell harm DIP diet.
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

AYURVEDIC MANAGEMENT OF CHRONIC LIVER DISEASE: A CASE STUDY
por: Acharya Manish, et al.
Publicado: (2026)

LIVER CIRRHOSIS: ETIOLOGY, PATHOGENESIS AND MODERN MANAGEMENT
por: Abdusamiyeva, Nargiza, et al.
Publicado: (2026)

Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)
por: Ida Schregel, et al.
Publicado: (2024)

Incidence of Nausea and Vomiting After Fast-Track Anaesthesia for Heart Surgery
por: Emad Mohamed Hijazi
Publicado: (2018)

Systematisch-anatomische Untersuchungen über die marsupialen Lebermoose der Sierra Nevada de Santa Marta in Kolumbien.
por: Winkler, S.
Publicado: (1969)

Analysis of the effectiveness of an antiemetic protocol used in an oncology division
por: M.J. Huertas-Fernández
Publicado: (2010)

Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
por: Legese Chelkeba
Publicado: (2017)

PERCUTANEOUS CATHETER DRAINAGE VERSUS NEEDLE ASPIRATION IN LIVER ABSCESS TREATMENT: A COMPARATIVE STUDY FROM A TERTIARY CARE HOSPITAL
por: Dr. Falak Naaz*, et al.
Publicado: (2025)

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
por: Xin Xiang, et al.
Publicado: (2026)

RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Internal Ribosome Entry Site‐Mediated Translation
Publicado: (2025)

The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability
por: Matthijs Vlasveld, et al.
Publicado: (2024)

Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
por: Rong Li, et al.
Publicado: (2025)

Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR ‐ MASH Score’
Publicado: (2024)

Reply: Herbal‐Induced Liver Injury Identification and Prevention
por: Dina Halegoua‐DeMarzio, et al.
Publicado: (2024)

Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice
por: Xiaofei Yin, et al.
Publicado: (2026)

Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD
por: Giovanni Targher, et al.
Publicado: (2025)

A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathological and Imaging Features With an Emphasis on β‐Catenin Mutated Subtype
por: Subin Heo, et al.
Publicado: (2024)

Bacterial Infections in Patients With Severe Alcohol‐Associated Hepatitis: Drivers of Organ Failure and Mortality
por: Laura Buttler, et al.
Publicado: (2025)

Expanding Perspectives on FIB ‐4 as a Predictor of Hepatic and Extrahepatic Malignancy Risk
por: Yuning Wang, et al.
Publicado: (2025)

Waitlist and transplant outcomes in patients with metabolic dysfunction‐associated steatotic liver disease and autoimmune hepatitis
por: Esli Medina‐Morales, et al.
Publicado: (2024)

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
por: David R. Riley, et al.
Publicado: (2024)

Gut‐Vascular Barrier Disruption: The Missing Link Between MASLD and Bacterial Infection
por: Wojciech Marlicz, et al.
Publicado: (2025)

TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma
por: Pingping Sun, et al.
Publicado: (2025)

Differential HBV replicative markers and covalently closed circular DNA transcription in immune‐active chronic hepatitis B with and without HBeAg
por: Hye Seon Kim, et al.
Publicado: (2024)

CACS , CCTA and mCAD‐LT score in the pre‐transplant assessment of coronary artery disease and the prediction of post‐transplant cardiovascular events
por: Giulia Pagano, et al.
Publicado: (2024)

Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study
por: Josh Bilson, et al.
Publicado: (2024)

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)
por: Oana Săndulescu, et al.
Publicado: (2026)

Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study
por: Maria Arechederra, et al.
Publicado: (2025)

PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease
por: Elizabeth K. Speliotes, et al.
Publicado: (2024)

Target Trial Emulations of GLP ‐1 and Dual GLP ‐1/ GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes
por: Alex E. Henney, et al.
Publicado: (2025)

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index
por: Mara Persano, et al.
Publicado: (2025)

Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium
por: Lara Buchardt, et al.
Publicado: (2025)

Large Language Models for Diagnosing Focal Liver Lesions From CT/MRI Reports: A Comparative Study With Radiologists
por: Liuji Sheng, et al.
Publicado: (2025)

Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Marco Castelli, et al.
Publicado: (2025)

Recompensation of Liver Cirrhosis by TIPS Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome
por: Felix Piecha, et al.
Publicado: (2024)

Response to Letter to the Editor: ‘Insights Into Comparison of Bacterial Infections in Patients With Cirrhosis Between Hospitals With and Without Liver Transplant’
por: Clàudia Torras, et al.
Publicado: (2025)

Reply to Reader—Pregnancy, Thyroid Disease Did Not Alter MASLD ‐Brain Aging Associations and Mediation of Inflammation
por: Jiao Wang, et al.
Publicado: (2025)

Metabolic Dysfunction‐Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda
por: Mohamed El‐Kassas, et al.
Publicado: (2025)

Does Competing‐Risk Modelling Appropriately Reflect the Bridging Role of Early RRT in Cirrhosis?
por: Tianqiang Sheng, et al.
Publicado: (2026)

The Novel BCS Score: Key Considerations on Variables, Endpoints and Generalisability
por: Xiangling Wei, et al.
Publicado: (2025)